Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28390632 | 0.88 | MAOB (0.60) | GFERCYP19A1ALOX15SMN1; SMN2MAOA | |
| SCHEMBL5255146 | 0.87 | TAAR1 (0.52) | TDP1GFERALDH1A1ALOX15TP53 | |
| SCHEMBL28814374 | 0.87 | TDP1 (0.42) | TDP1MEN1KMT2AGFERSKP2 | |
| SCHEMBL5604961 | 0.85 | SKP2 (0.53) | TDP1MEN1KMT2AGFERSKP2 | |
| SCHEMBL27931206 | 0.85 | TDP1 (0.40) | TDP1MEN1KMT2AGFERSKP2 | |
| SCHEMBL4720461 | 0.85 | ALDH1A1 (0.52) | TDP1MEN1KMT2ASKP2CYP19A1 | |
| SCHEMBL28127455 | 0.85 | SLC6A2 (0.43) | TDP1MEN1KMT2AGFERSKP2 | |
| SCHEMBL1519089 | 0.85 | SKP2 (0.44) | TDP1MEN1KMT2AGFERSKP2 | |
| SCHEMBL295465 | 0.82 | CYP3A4 (0.61) | TDP1MEN1KMT2AGFERSKP2 | |
| SCHEMBL29799746 | 0.82 | CYP3A4 (0.61) | TDP1MEN1KMT2AGFERSKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318376-B1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2318376-B1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| US-7906655-B2 | 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906655-B2 | 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906655-B2 | 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-5773197-A | Integrated circuit device and process for its manufacture | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0293091-B1 | POLY(AMIDE-BENZAZOLES) | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-01-13 | — | — | EP | disclosed |
| US-4448954-A | Single stage production of improved high molecular weight polybenzimidazole with organosilicon halide catalyst. | CELANESE CORPORATION (US) | 1984-05-15 | — | — | US | disclosed |
| EP-0103978-A1 | Single stage production of improved high molecular weight polybenzimidazole | CELANESE CORPORATION (US) | 1984-03-28 | — | — | EP | disclosed |
| US-4431796-A | HEATING A MELT OF AROMATIC TETRAAMINE AND AROMATIC DICARBOXYLIC AC | CELANESE CORPORATION (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0095348-A2 | High molecular weight polybenzimidazoles | CELANESE CORPORATION (US) | 1983-11-30 | — | — | EP | disclosed |
| US-4414383-A | High molecular weight polybenzimidazole preparation with phosphorus containing polymerization catalyst | CELANESE CORPORATION (US) | 1983-11-08 | — | — | US | disclosed |
| US-4113683-A | Production of high temperature resistant polymer compositions capable of forming superior fiber reinforced composite articles | CELANESE CORPORATION (US) | 1978-09-12 | — | — | US | disclosed |
| US-3987015-A | PROCESS FOR THE PRODUCTION OF PARTICULATE POLYMERIC MATERIAL HAVING AN UNUSUALLY HIGH SURFACE AREA | CELANESE CORPORATION (US) | 1976-10-19 | — | — | US | disclosed |
| US-3985679-A | POLY(BISBENIMIDAZOBENZOPHENANTHROLINE) | CELANESE CORPORATION (US) | 1976-10-12 | — | — | US | disclosed |
| US-3969325-A | Production of particulate BBB type polymer having an unusually high surface area | CELANESE CORPORATION (US) | 1976-07-13 | — | — | US | disclosed |
| US-3969430-A | Processability of intractable polymers | CELANESE CORPORATION (US) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | TDP1 3331/4885MEN1 4867/4885KMT2A 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.